Ultra Rapidly Dissolving Repaglinide Nanosized Crystals Prepared via Bottom-Up and Top-Down Approach: Influence of Food on Pharmacokinetics Behavior

AAPS PharmSciTech

Volumn 16, Issue 4, 2015, Pages 787-799

  Gadadare, Rahul ^a   Mandpe, Leenata ^a   Pokharkar, Varsha ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

diabetes mellitus; fasted and fed state variability; nanocrystal; oral hypoglycemic activity; repaglinide

Indexed keywords

GLUCOSE; NANOCRYSTAL; REPAGLINIDE; ANTIDIABETIC AGENT; CARBAMIC ACID DERIVATIVE; NANOPARTICLE; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CRITICAL MICELLE CONCENTRATION; DISPERSION; DOWNSTREAM PROCESSING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONCENTRATION; DRUG SOLUBILITY; FOOD INTAKE; GLUCOSE BLOOD LEVEL; ISOELECTRIC POINT; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PARTICLE SIZE; PH; PRIORITY JOURNAL; RAT; REFRACTION INDEX; SOLUBILIZATION; STOMACH JUICE; THERMOGRAPHY; X RAY DIFFRACTION; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; CHEMISTRY; FOOD DRUG INTERACTION; WISTAR RAT;

ANIMALS; BIOLOGICAL AVAILABILITY; CARBAMATES; FOOD-DRUG INTERACTIONS; HYPOGLYCEMIC AGENTS; MALE; NANOPARTICLES; PIPERIDINES; RATS; RATS, WISTAR;

EID: 84937796764     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-014-0267-8     Document Type: Article

References (45)

1. International Diabetes Federation. 2011: 5th ed.; www.idf.org/diabetesatlas/papers. Accessed 28 April 2014
2. Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet. 2002;41:471–83. doi:10.2165/00003088-200241070-00002.
3. Nattrass M, Lauritzen T. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes. Int J Obes Relat Metab Disord. 2000;24 Suppl 3:S21–31. doi:10.1038/sj.ijo.0801422.
4. Mandic Z, Gabelica V. Ionization, lipophilicity and solubility properties of repaglinide. J Pharm Biomed Anal. 2006;41:866–71. doi:10.1016/j.jpba.2006.01.056.
5. Hatorp V, Oliver S, Su CA. Bioavailability of repaglinide, a novel anti-diabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers. Int J Clin Pharmacol Ther. 1998;36:636–41.
6. Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol. 2008;56:305–14. doi:10.1046/j.0306-5251.2003.01862.x.
7. Chang C, Bahadduri PM, Polli JE, Swaan PW, Ekins S. Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos. 2006;34:1976–84. doi:10.1124/dmd.106.012351.
8. Hatorp V, Bayer T. Repaglinide bioavailability in the fed or fasting state [abstract]. J Clin Pharmacol. 1997;37:875.
9. Yuan G, Jiao L, Xuan Q, Jianjun Z. Co-amorphous repaglinide—saccharin with enhanced dissolution. Int J Pharm. 2013;450:290–5. doi:10.1016/j.ijpharm.2013.04.032.
10. Kavitha R, Sathali AAH. Enhancement of solubility of repaglinide by solid dispersion technique. Int J Chem Sci. 2012;10:377–90.
11. Nicolescu C, Arama C, Nedelcu A, Monciu CM. Phase solubility studies of the inclusion complexes of repaglinide with β-cyclodextrin and β-cyclodextrin derivatives. Farmacia. 2010;58:620–8.
12. Troy P, Michal E, Mattucci M, Todd C, Keith P, Williams RO. Rapidly dissolving repaglinide powders produced by the ultra-rapid freezing process. AAPS PharmSciTech 2007; 8: Article 58. doi: 10.1208/pt0803058
13. Junghanns AH, Muller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine. 2008;3:295–309. doi:10.2147/IJN.S595.
14. Peltonen L, Hirvonen J. Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods. J Pharm Pharmacol. 2010;62:1569–79. doi:10.1111/j.2042-7158.2010.01022.x.
15. Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs 1: absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm. 1995;125:91–7. doi:10.1016/0378-5173(95)00122-Y.
16. Hardung H, Djuric D, Ali S. Combining HME and solubilisation-soluplus—the solid solution. Drug Deliv Technol. 2010;10:20–7.
17. Dintaman JM, Silverman JA. Inhibition of P-glycoprotein by of d-α-tocopheryl PEG 1000 succinate (TPGS). Pharm Res. 1999;16:1550–6. doi:10.1023/A:1015000503629.
18. Yu L, Bridgers A, Polli J, Vickers A, Long S, Roy A. Vitamin E TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm Res. 1999;16:1812–7. doi:10.1023/A:1018939006780.
19. Wu SHW, Hopkins WK. Characteristics of d-α-tocopheryl PEG 1000 succinate for applications as an absorption enhancer in drug delivery systems. Pharm Technol. 1999;23:52–68.
20. Verma VSM, Panchagnula R. Enhanced paclitaxel oral absorption with Vitamin E-TPGS: effect on solubility and permeability in vitro, in situ, in vivo. Eur J Pharm Sci. 2005;25:445–53. doi:10.1016/j.ejps.2005.04.003.
21. Christiansen A, Backensfeld T, Denner K, Weitschies W. Effects of non-ionic surfactants on cytochrome P450-mediated metabolism in vitro. Eur J Pharm Biopharm. 2011;78:166–72. doi:10.1016/j.ejpb.2010.12.033.
22. Johnson BM, Charman WN, Porter CJH. An in vitro examination of the impact of polyethylene glycol 400, pluronic P85 and vitamin E D-α-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS PharmSciTech. 2002;4:E40. doi:10.1208/ps040440.
23. Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage. Pharm Res. 1998;15:11–22. doi:10.1023/A:1011984216775.
24. Jantratid E, Janssen N, Chokshi H, Tang K, Dressman J. Designing bio-relevant dissolution tests for lipid formulations: case example—lipid suspension of RZ-50. Eur J Pharm Biopharm. 2008;69:776–85. doi:10.1016/j.ejpb.2007.12.010.
25. Verma S, Gokhale R, Burgess DJ. A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions. Int J Pharm. 2009;380:216–22. doi:10.1016/j.ijpharm.2009.07.005.
26. He W, Lu Y, Qi JP, Chen LY, Hu FQ, Wu W. Food proteins as novel nanosuspension stabilizers for poorly water-soluble drugs. Int J Pharm. 2013;441:269–78. doi:10.1016/j.ijpharm.2012.11.033.
27. ICH Harmonised Tripartite Guideline. Stability testing of new drug substances and products Q1A (R2), version 4 dated 6 February, 2003
28. Cerdeira AM, Mazzotti M, Bruno G. Miconazole nanosuspensions: influence of formulation variables on particle size reduction and physical stability. Int J Pharm. 2010;396:210–8. doi:10.1016/j.ijpharm.2010.06.020.
29. Jinno J, Kamada N, Miyake M, Yamada K, Mukai T, Odomi M. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release. 2006;111:56–64. doi:10.1016/j.jconrel.2005.11.013.
30. Rahigude A, Bhutada P, Kaulaskar S, Aswar M, Otari K. Participation of antioxidant and cholinergic system in protective effect of naringenin against type-2 diabetes-induced memory dysfunction in rats. Neuroscience. 2012;226:62–72. doi:10.1016/j.neuroscience.2012.09.026.
31. Ruzilawati AB, Wahab MSA, Imran A, Ismail Z, Gana SH. Method development and validation of repaglinide in human plasma by HPLC and its application in pharmacokinetic studies. J Pharm Biomed Anal. 2007;43:1831–5. doi:10.1016/j.jpba.2006.12.010.
32. Amrani FE, Rhallab A, Alaoui T, Badaoui KE, Chakir S. Hypoglycaemic effect of Thymelaea hirsuta in normal and streptozotocin-induced diabetic rat. J Med Plants Res. 2009;3:625–9.
33. Andrade-Cetto A, Wiedenfeld H, Revilla MC, Islas S. Hypoglycaemic effect of Equisetum myriochaetum aerial parts on streptozotocin diabetic rats. J Ethnopharmacol. 2000;72:129–33. doi:10.1016/S0378-8741(00)00218-X.
34. Kipp JE, Wong T, Chung J, Doty MJ, Werling J, Rebbeck CL. Method for preparing submicron particle suspension. U S Patent. 2005;6:884,436.
35. Guo Z, Zhang M, Li H, Wang J, Kougoulos E. Effect of ultrasound on antisolvent crystallisation process. J Cryst Growth. 2005;273:555–63. doi:10.1016/j.jcrysgro.2004.09.049.
36. Dhumal RS, Biradar SV, Paradkar AR, York P. Particle engineering using sonocrystallization: salbutamol sulphate for pulmonary delivery. Int J Pharm. 2009;368:129–37. doi:10.1016/j.ijpharm.2008.10.006.
37. Yao JH, Elder KR, Guo H, Grant M. Theory and simulation of Ostwald ripening. Physical review B. 1993;47(21):110–25. doi:10.1103/PhysRevB.47.14110.
38. Teeranachaideekul V, Junyaprasert V, Souto E, Muller R. Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology. Int J Pharm. 2008;354:227–34. doi:10.1016/j.ijpharm.2007.11.062.
39. Kesisoglou F, Panmai S, Wu Y. Nanosizing—oral formulation development and biopharmaceutical evaluation. Adv Drug Del Rev. 2007;59:631–44. doi:10.1016/j.addr.2007.05.003.
40. Gao L, Liu G, Ma J, Wang X, Zhou L, Li X. Drug nanocrystals: in vivo performances. J Control Release. 2012;160:418–30. doi:10.1016/j.jconrel.2012.03.013.
41. Li Xi G, Xu Y, Wang Y. Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behaviour in rats. Drug Dev Ind Pharm. 2009;35:827–33. doi:10.1080/03639040802623941.
42. Parsa A, Saadati R, Abbasian Z, Aramaki SA, Dadashzadeh S. Enhanced permeability of etoposide across everted sacs of rat small intestine by vitamin E-TPGS. Iranian J Pharm Res. 2013;12:37–46.
43. Rege BD, Kao JPY, Polli JE. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci. 2002;16:237–46. doi:10.1016/S0928-0987(02)00055-6.
44. Ivora MD, Paya M, Villar A. A review of natural products and plants as potential anti-diabetic drugs. J Ethnopharmacol. 1989;27:243–75. doi:10.1016/0378-8741(89)90001-9.
45. Sharma SR, Dwivedi SK, Swarup D. Hypoglycaemic, anti hyperglycaemic and hypolipidemic activities of Cesalpinia bounducella seeds in rats. J Ethnopharmacol. 1997;58:39–44. doi:10.1016/S0378-8741(97)00079-2.